INAB vs. CYTH, DYAI, OKYO, QNCX, HCWB, SABS, ESLA, ACHL, TARA, and INKT
Should you be buying IN8bio stock or one of its competitors? The main competitors of IN8bio include Cyclo Therapeutics (CYTH), Dyadic International (DYAI), OKYO Pharma (OKYO), Quince Therapeutics (QNCX), HCW Biologics (HCWB), SAB Biotherapeutics (SABS), Estrella Immunopharma (ESLA), Achilles Therapeutics (ACHL), Protara Therapeutics (TARA), and MiNK Therapeutics (INKT). These companies are all part of the "medical" sector.
Cyclo Therapeutics (NASDAQ:CYTH) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, community ranking, media sentiment, analyst recommendations, risk, dividends and valuation.
IN8bio has a net margin of 0.00% compared to IN8bio's net margin of -1,720.76%. Cyclo Therapeutics' return on equity of -151.40% beat IN8bio's return on equity.
Cyclo Therapeutics has a beta of -0.18, indicating that its stock price is 118% less volatile than the S&P 500. Comparatively, IN8bio has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500.
In the previous week, IN8bio had 5 more articles in the media than Cyclo Therapeutics. MarketBeat recorded 8 mentions for IN8bio and 3 mentions for Cyclo Therapeutics. IN8bio's average media sentiment score of 1.00 beat Cyclo Therapeutics' score of 0.31 indicating that Cyclo Therapeutics is being referred to more favorably in the media.
68.6% of Cyclo Therapeutics shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 29.8% of Cyclo Therapeutics shares are owned by insiders. Comparatively, 33.0% of IN8bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
IN8bio received 13 more outperform votes than Cyclo Therapeutics when rated by MarketBeat users. However, 77.78% of users gave Cyclo Therapeutics an outperform vote while only 68.97% of users gave IN8bio an outperform vote.
Cyclo Therapeutics has higher revenue and earnings than IN8bio. Cyclo Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.
Cyclo Therapeutics presently has a consensus target price of $3.20, suggesting a potential upside of 128.57%. IN8bio has a consensus target price of $10.00, suggesting a potential upside of 870.87%. Given Cyclo Therapeutics' higher probable upside, analysts clearly believe IN8bio is more favorable than Cyclo Therapeutics.
Summary
IN8bio beats Cyclo Therapeutics on 11 of the 16 factors compared between the two stocks.
Get IN8bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for INAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding INAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
